Abstract
Gains in overall and progression-free survival (OS, PFS) and a higher objective response rate were observed in the CASPIAN trial of patients with extensive-stage small-cell lung cancer who received durvalumab in combination with etoposide and platinum-based chemotherapy (D+EP) compared with EP alone. However, the extent to which response predicts long-term survival is unknown. We defined response/non-response at different landmark times and derived OS and PFS during follow-up after each landmark among D+EP and EP patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
